drugset / Trial / NCT00028678

Dalteparin and Radiation Therapy in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme

NCT00028678

Treatment

Summary

RATIONALE: Dalteparin may stop the growth of cancer by stopping blood flow to the tumor and by blocking the enzymes necessary for tumor cell growth. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining dalteparin with radiation therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining dalteparin with radiation therapy in treating patients who have newly diagnosed supratentorial glioblastoma multiforme.

Timeline

Start
2002-07-11
Primary completion
2006-07
Completion
2007-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Dalteparin sodium Other / unclassified 5000 iu Subcutaneous